LAVA THERAPEUTICS NV(NASDAQ:LVTX) stock News

LVTX Latest News, Press Relases and Analysis

All

Press Releases

19 days ago - By: Chartmill - Mentions: FGL TTNP ASNS ABP ...

Thursday's after hours session: top gainers and losers

a day ago - By: Ademi LLP

Shareholder Alert: The Ademi Firm investigates whether LAVA Therapeutics N.V. is obtaining a Fair Price for its Public Shareholders in the Amendment to the Purchase Agreement

4 days ago - By: Stocktwits - Mentions: XOMA

LAVA Therapeutics Stock Drops After Amended Deal With XOMA Royalty

4 days ago - By: XOMA Royalty Corporation; LAVA Therapeutics N.V. - Mentions: XOMA

XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement

19 days ago - By: XOMA Royalty Corporation; LAVA Therapeutics - Mentions: XOMA

XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.

22 days ago - By: Stocktwits - Mentions: XOMA

LAVA Therapeutics Stock Slips 9% Pre-Market – Here’s Why The Company Canceled Its Shareholder Meeting

22 days ago - By: LAVA Therapeutics N.V.

LAVA Therapeutics to Move Extraordinary General Meeting to Early November 2025

2 months ago - By: Benzinga - Mentions: CSBR CAPR TCRT

4 Biotech Stocks That Are Showing Weakness: Momentum Scores Fading Over The Past Week

2 months ago - By: LAVA Therapeutics N.V.

LAVA Reports Second Quarter 2025 Financial Results and Provides Corporate Update

2 months ago - By: Halper Sadeh LLP - Mentions: SCS

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SCS, LVTX, ENZB on Behalf of Shareholders

3 months ago - By: Benzinga - Mentions: INSP IP NVO XYZ

This Block Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

3 months ago - By: Brodsky & Smith LLC - Mentions: HLVX SCS RKDA XOMA ...

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: HilleVax, Inc. (Nasdaq – HLVX), Steelcase Inc. (NYSE – SCS), LAVA Therapeutics N.V. (Nasdaq – LVTX), Arcadia Biosciences, Inc. (Nasdaq – RKDA)

3 months ago - By: Halper Sadeh LLC

LVTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Lava Therapeutics N.V. Is Fair to Shareholders

3 months ago - By: XOMA Royalty Corporation; LAVA Therapeutics N.V. - Mentions: XOMA

XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right

5 months ago - By: LAVA Therapeutics N.V.

LAVA Reports First Quarter 2025 Financial Results, Provides Business Update

6 months ago - By: LAVA Therapeutics N.V.

LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation

7 months ago - By: LAVA Therapeutics N.V.

LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

9 months ago - By: LAVA Therapeutics N.V.

LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers

11 months ago - By: LAVA Therapeutics N.V.

LAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension into 2027

a year ago - By: LAVA Therapeutics N.V.

LAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

a year ago - By: InvestorPlace

LVTX Stock Earnings: LAVA Therapeutics Beats EPS for Q2 2024

a year ago - By: BusinessInsider

LVTX Stock Earnings: LAVA Therapeutics Beats EPS for Q2 2024

a year ago - By: LAVA Therapeutics N.V.

LAVA Reports Second Quarter 2024 Financial Results and Business Update

a year ago - By: LAVA Therapeutics N.V.

LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

a year ago - By: LAVA Therapeutics N.V.

LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

a year ago - By: LAVA Therapeutics N.V.

LAVA Announces Annual Meeting of Shareholders

a year ago - By: LAVA Therapeutics N.V.

LAVA Announces Annual Meeting of Shareholders

a year ago - By: LAVA Therapeutics N.V.

LAVA Therapeutics to Participate in the Jefferies Global Healthcare Conference

a year ago - By: InvestorPlace

LVTX Stock Earnings: LAVA Therapeutics Beats EPS, Misses Revenue for Q1 2024

a year ago - By: BusinessInsider

LVTX Stock Earnings: LAVA Therapeutics Beats EPS, Misses Revenue for Q1 2024

a year ago - By: LAVA Therapeutics N.V.

LAVA Provides Business Updates and Reports First Quarter 2024 Financial Results

a year ago - By: LAVA Therapeutics N.V.

LAVA Provides Business Updates and Reports First Quarter 2024 Financial Results

a year ago - By: LAVA Therapeutics N.V.

LAVA THERAPEUTICS NV (LVTX) Stock News

LVTX Latest News, Press Relases and Analysis

Thursday's after hours session: top gainers and losers

Shareholder Alert: The Ademi Firm investigates whether LAVA Therapeutics N.V. is obtaining a Fair Price for its Public Shareholders in the Amendment to the Purchase Agreement

LAVA Therapeutics Stock Drops After Amended Deal With XOMA Royalty

XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement

XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.

LAVA Therapeutics Stock Slips 9% Pre-Market – Here’s Why The Company Canceled Its Shareholder Meeting

LAVA Therapeutics to Move Extraordinary General Meeting to Early November 2025

4 Biotech Stocks That Are Showing Weakness: Momentum Scores Fading Over The Past Week

LAVA Reports Second Quarter 2025 Financial Results and Provides Corporate Update

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SCS, LVTX, ENZB on Behalf of Shareholders

This Block Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: HilleVax, Inc. (Nasdaq – HLVX), Steelcase Inc. (NYSE – SCS), LAVA Therapeutics N.V. (Nasdaq – LVTX), Arcadia Biosciences, Inc. (Nasdaq – RKDA)

LVTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Lava Therapeutics N.V. Is Fair to Shareholders

XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right

LAVA Reports First Quarter 2025 Financial Results, Provides Business Update

LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation

LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers

LAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension into 2027

LAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

LVTX Stock Earnings: LAVA Therapeutics Beats EPS for Q2 2024

LVTX Stock Earnings: LAVA Therapeutics Beats EPS for Q2 2024

LAVA Reports Second Quarter 2024 Financial Results and Business Update

LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

LAVA Announces Annual Meeting of Shareholders

LAVA Announces Annual Meeting of Shareholders

LAVA Therapeutics to Participate in the Jefferies Global Healthcare Conference

LVTX Stock Earnings: LAVA Therapeutics Beats EPS, Misses Revenue for Q1 2024

LVTX Stock Earnings: LAVA Therapeutics Beats EPS, Misses Revenue for Q1 2024

LAVA Provides Business Updates and Reports First Quarter 2024 Financial Results

LAVA Provides Business Updates and Reports First Quarter 2024 Financial Results

LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference